Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
236.2
USD
|
+4.67%
|
|
+2.87%
|
+2.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,406
|
1,719
|
1,449
|
5,179
|
4,568
|
5,033
|
-
|
-
|
Enterprise Value (EV)
1 |
966.7
|
1,436
|
1,179
|
4,869
|
4,051
|
4,339
|
4,741
|
4,516
|
P/E ratio
|
-16.7
x
|
-8.49
x
|
-5.79
x
|
-16.8
x
|
-11.6
x
|
-8.33
x
|
-13
x
|
59.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
66.4
x
|
13.9
x
|
5.25
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
57.3
x
|
13.1
x
|
4.71
x
|
EV / EBITDA
|
-10.2
x
|
-6.96
x
|
-4.87
x
|
-16.6
x
|
-10.7
x
|
-7.12
x
|
-9.43
x
|
-28.3
x
|
EV / FCF
|
-23.1
x
|
-9.09
x
|
-4.87
x
|
-16.6
x
|
-12.4
x
|
-7.36
x
|
-10.9
x
|
-26.2
x
|
FCF Yield
|
-4.32%
|
-11%
|
-20.6%
|
-6.01%
|
-8.04%
|
-13.6%
|
-9.16%
|
-3.81%
|
Price to Book
|
3.37
x
|
7.18
x
|
7.15
x
|
26.6
x
|
11.3
x
|
9.26
x
|
49.1
x
|
17.7
x
|
Nbr of stocks (in thousands)
|
15,429
|
15,466
|
17,097
|
17,842
|
19,743
|
21,312
|
-
|
-
|
Reference price
2 |
91.11
|
111.2
|
84.74
|
290.2
|
231.4
|
236.2
|
236.2
|
236.2
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
75.76
|
361.1
|
959.4
|
EBITDA
1 |
-94.86
|
-206.2
|
-242.1
|
-293.1
|
-380
|
-609.7
|
-502.6
|
-159.8
|
EBIT
1 |
-94.97
|
-206.7
|
-242.5
|
-293.6
|
-380.5
|
-602.5
|
-413.7
|
125.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-795.35%
|
-114.57%
|
13.04%
|
Earnings before Tax (EBT)
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-598
|
-414.7
|
112
|
Net income
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-583
|
-403.2
|
97.71
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-769.54%
|
-111.66%
|
10.18%
|
EPS
2 |
-5.450
|
-13.09
|
-14.63
|
-17.23
|
-19.99
|
-28.34
|
-18.20
|
3.959
|
Free Cash Flow
1 |
-41.8
|
-157.9
|
-242.3
|
-292.5
|
-325.7
|
-589.6
|
-434.3
|
-172.1
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-778.22%
|
-120.27%
|
-17.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.692
|
22.07
|
49.99
|
58.65
|
75.13
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-78.21
|
-
|
-
|
-
|
-151.9
|
-138
|
-134.8
|
-124.4
|
-
|
-
|
EBIT
1 |
-64.6
|
-57.59
|
-70.27
|
-80.41
|
-85.3
|
-78.34
|
-86.45
|
-98.53
|
-117.2
|
-152
|
-163.4
|
-155.1
|
-131.6
|
-139.3
|
-127.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,425.31%
|
-702.74%
|
-263.35%
|
-237.55%
|
-169.46%
|
Earnings before Tax (EBT)
1 |
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-162.2
|
-154.6
|
-131.7
|
-137.5
|
-126.5
|
Net income
1 |
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-157.7
|
-149.8
|
-128.4
|
-137.5
|
-126.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,271.44%
|
-678.71%
|
-256.84%
|
-234.51%
|
-168.41%
|
EPS
2 |
-3.790
|
-3.360
|
-4.140
|
-4.750
|
-4.980
|
-4.230
|
-4.690
|
-5.340
|
-5.680
|
-7.380
|
-7.654
|
-7.188
|
-6.084
|
-6.382
|
-5.844
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/9/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/9/23
|
8/8/23
|
11/6/23
|
2/28/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
439
|
284
|
270
|
309
|
517
|
694
|
292
|
517
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-41.8
|
-158
|
-242
|
-293
|
-326
|
-590
|
-434
|
-172
|
ROE (net income / shareholders' equity)
|
-18.8%
|
-61.6%
|
-111%
|
-
|
-124%
|
-122%
|
-157%
|
-80.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.00
|
15.50
|
11.90
|
10.90
|
20.40
|
25.50
|
4.810
|
13.30
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-17.60
|
-14.00
|
-
|
Capex
1 |
0.17
|
0.33
|
0.21
|
0.22
|
1.48
|
2.07
|
2.36
|
2.25
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
2.74%
|
0.65%
|
0.23%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
236.2
USD Average target price
363.9
USD Spread / Average Target +54.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.07% | 5.03B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.03% | 21.96B | | -8.05% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|